February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...
A study at Lund University reveals that traumatic brain injury alters the small vessels in the brain, resulting in an accumulation of amyloid beta—a hallmark of Alzheimer's disease. The findings ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way to measure the effect ...
New serine biomarkers show promise for early Alzheimer's detection, linking tau assemblies to cognitive decline and offering ...
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new ...
Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms ...
Researchers from the Centre for Addiction and Mental Health (CAMH) and affiliated organizations presented preclinical data for the α5-GABA-A receptor (α5-GABAAR) positive allosteric modulator GL-II-73 ...
Su Jin Yim and colleagues argue that with the proposed definition of Alzheimer’s disease (AD) expanding in the most recent ...
Years before tau tangles show up in brain scans of patients with Alzheimer's disease, a biomarker test developed at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback